Evidence map›Paper›PMID 31205525›Full record

ArticleJournal of Cancer2019

Peptide V3 Inhibits the Growth of Human Hepatocellular Carcinoma by Inhibiting the Ras/Raf/MEK/ERK Signaling Pathway.

Dongdong Wu, Mengling Li, Yingran Gao, Wenke Tian, Jianmei Li, Qianqian Zhang, Zhengguo Liu, Mengli Zheng, Hongju Wang, Jun Wang and 6 more

Abstract read
In one paragraph

Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dongdong WuSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Mengling LiSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Yingran GaoSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Wenke TianSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Jianmei LiSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Qianqian ZhangSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Zhengguo LiuSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Mengli ZhengSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Hongju WangSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Jun WangSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Tieshan TengSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Lei ZhangSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Xinying JiSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Zhongwen XieState Key Laboratory of Tea Plant Biology and Utilization, Anhui Agricultural University, 130 Changjiang West Road, Hefei, Anhui 230036, China.
Ailing JiSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.
Yanzhang LiSchool of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths. Peptide V3 has shown anti-angiogenic and anti-tumor effects on S180 and H22 xenografts in nude mice. However, the detailed mechanism of action of peptide V3 has not yet been fully elucidated. In the present study, the effects of peptide V3 on the growth of human HCC cells were examined both

Indexed as

angiogenesisapoptosisHCCpeptide V3signaling pathway

Identifiers

PMID31205525
PMCPMC6548006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.